Synergistic Activity of 3-Hydrazinoquinoxaline-2-Thiol in Combination with Penicillin Against MRSA

References

• Hu Y, Liu Y, Coates A. Azidothymidine produces synergistic activity in combination with colistin against antibiotic-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63(1):1–11. doi:10.1128/AAC.01630-18
   Web of Science ®Google Scholar
• Butterly A, Schmidt U, Ph D, Wiener-kronish J. Methicillin-resistant Staphylococcus aureus colonization, its relationship to nosocomial infection, and efficacy of control methods. Anesthesiol J Am Soc Anesthesiol. 2010;113:1453–1459.
   PubMed Web of Science ®Google Scholar
• Bush K, Bradford PA. β-Lactams and β-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8):a025247. doi:10.1101/cshperspect.a025247
   PubMed Web of Science ®Google Scholar
• Stapleton PD, Taylor PW. Methicillin resistance in Staphylococcus aureus: mechanisms and modulation. Sci Prog. 2007;85:1–14.
   Google Scholar
• Meyer E, Schwab F, Gastmeier P. Nosocomial methicillin resistant Staphylococcus aureus pneumonia-epidemiology and trends based on data of a network of 586 German ICUs (2005–2009). Eur J Med Res. 2010;15(12):514–524. doi:10.1186/2047-783X-15-12-514
   PubMed Web of Science ®Google Scholar
• Nguyen HM, Graber CJ. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J Antimicrob Chemother. 2009;65(1):24–36. doi:10.1093/jac/dkp377
   Web of Science ®Google Scholar
• Pantosti A, Sanchini A, Monaco M. Mechanisms of antibiotic resistance in Staphylococcus aureus. Future Microbiol. 2007;2(3):323–334. doi:10.2217/17460913.2.3.323
   PubMed Web of Science ®Google Scholar
• Ventola CL. The antibiotic resistance crisis part 1: causes and threats. Pharm Ther. 2015;40:277–283.
   Google Scholar
• Gonzales PR. Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA. Nat Chem Biol. 2015;11(11):855–861. doi:10.1038/nchembio.1911
   PubMed Web of Science ®Google Scholar
• Kerantzas CA, Jacobs WR, Rubin EJ, Collier RJ. Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application. MBio. 2017;8(2):1–10. doi:10.1128/mBio.01586-16
   Web of Science ®Google Scholar
• Ramo S, Ng C, Anderson H, et al. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. Antimicrob Agents Chemother. 2011;55(8):3861–3869. doi:10.1128/AAC.00474-11
   PubMed Web of Science ®Google Scholar
• Elfadil A, Alzahrani AM, Abdullah H, et al. Evaluation of the antibacterial activity of quinoxaline derivative compound against methicillin-resistant Staphylococcus aureus. Infect Drug Resist. 2023;16:2291–2296. doi:10.2147/IDR.S401371
   PubMed Web of Science ®Google Scholar
• Ahammed KS, Pal R, Chakraborty J, et al. DNA structural alteration leading to antibacterial properties of 6-nitroquinoxaline derivatives. J Med Chem. 2019;62(17):7840–7856. doi:10.1021/acs.jmedchem.9b00599
   PubMed Web of Science ®Google Scholar
• Tan CM, Therien AG, Lu J, et al. Restoring Methicillin-Resistant Staphylococcus aureus Susceptibility to β-Lactam Antibiotics. Sci Transl Med. 2012;4(126):126ra35. doi:10.1126/scitranslmed.3003592
   PubMed Web of Science ®Google Scholar
• Mikkelsen K, Sirisarn W, Alharbi O, et al. The novel membrane-associated auxiliary factors AuxA and AuxB modulate β -lactam resistance in MRSA by stabilizing lipoteichoic acids. Int J Antimicrob Agents. 2021;57(3):106283. doi:10.1016/j.ijantimicag.2021.106283
   PubMed Web of Science ®Google Scholar
• Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review. Front Microbiol. 2019;10. doi:10.3389/fmicb.2019.00539
   PubMed Web of Science ®Google Scholar
• Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018;4(3):482–501. doi:10.3934/microbiol.2018.3.482
   PubMed Web of Science ®Google Scholar
• Cheng G, Sa W, Cao C, et al. Quinoxaline 1,4-di-N-oxides: biological activities and mechanisms of actions. Front Pharmacol. 2016;7:1–21. doi:10.3389/fphar.2016.00064
   PubMed Web of Science ®Google Scholar
• Uddin TM, Chakraborty AJ, Khusro A, et al. Antibiotic resistance in microbes: history, mechanisms, therapeutic strategies and future prospects. J Infect Public Health. 2021;14(12):1750–1766. doi:10.1016/j.jiph.2021.10.020
   PubMed Web of Science ®Google Scholar
• Moellering RC, Weinberg AN, Weinberg AN. Studies on antibiotic synergism against enterococci: II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest. 1971;50(12):2580–2584. doi:10.1172/JCI106758
   PubMed Web of Science ®Google Scholar
• Dwyer DJ, Belenky PA, Yang JH, et al. Antibiotics induce redox-related physiological alterations as part of their lethality. Proc Natl Acad Sci. 2014;111(20):E2100–E2109. doi:10.1073/pnas.1401876111
   PubMed Web of Science ®Google Scholar
• Chacón-Vargas KF, Andrade-Ochoa S, Nogueda-Torres B, et al. Isopropyl quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives induce regulated necrosis-like cell death on Leishmania (Leishmania) mexicana. Parasitol Res. 2018;117(1):45–58. doi:10.1007/s00436-017-5635-3
   PubMed Web of Science ®Google Scholar
• Léger L, Budin-Verneuil A, Cacaci M, Benachour A, Hartke A, Verneuil N. β-lactam exposure triggers reactive oxygen species formation in enterococcus faecalis via the respiratory chain component DMK. Cell Rep. 2019;29(8):2184–2191. doi:10.1016/j.celrep.2019.10.080
   PubMed Web of Science ®Google Scholar
• Rani R, Sharma D, Chaturvedi M, Parkash Yadav J. Antibacterial activity of twenty different endophytic fungi isolated from calotropis procera and time kill assay. Clin Microbiol Open Access. 2017;06(03). doi:10.4172/2327-5073.1000280
   Google Scholar
• Duan L, Zhang J, Chen Z, et al. Antibiotic combined with epitope-specific monoclonal antibody cocktail protects mice against bacteremia and acute pneumonia from methicillin-resistant staphylococcus aureus infection. J Inflamm Res. 2021;14:4267–4282. doi:10.2147/JIR.S325286
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–12. doi:10.1086/516284
   PubMed Web of Science ®Google Scholar